Alcon Labs uses brains to test ad effectiveness

Using only 20 respondents, Alcon Laboratories was able to measure the effectiveness of a DTC ad with enough accuracy to significantly improve its impact on the audience.

How was this possible? Alcon tapped neuroscience firm NeuroFocus to test the effectiveness of ads for its Pataday allergies solution by directly measuring signals from viewers' brains.

CEO Dr. A.K. Pradeep told delegates at last month's PMRG conference in Las Vegas that NeuroFocus uses a “baseball cap” with 64 sensors to measure attention levels, emotional engagement and memory retention up to 2,000 times a second. From this, the firm derives three metrics: purchase intent, novelty and awareness/understanding.

Because each  response is “subconscious” and delivered in one-third of a second, Dr. Pradeep described it as “a scientific measurement without biases and pitfalls. A sample size of 20 will produce 20 perfect responses.”
NeuroFocus was able to make several key recommendations: to emphasize “relief” and “once a day”(the strongest messages); to drop “new”; to focus on different messages for men and women; and to opt for frequency with the media buy.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.